EVM
VIR icon

Eaton Vance Management’s Vir Biotechnology VIR Stock Holding History

Eaton Vance Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-37,816
Closed -$972K – 1813
2022
Q1 		$972K Buy
37,816
+37,696
+31,413% +$1.12M ﹤0.01% 1372
2021
Q4 		$5K Sell
120
-17
-12% -$666 ﹤0.01% 2654
2021
Q3 		$0 Buy
137
+39
+40% +$1.69K ﹤0.01% 2704
2021
Q2 		$5K Sell
98
-205
-68% -$9.32K ﹤0.01% 2642
2021
Q1 		$16K Buy
+303
New +$16.3K ﹤0.01% 2185

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Eaton Vance Management's VIR Position: Q2 2022 in Review

Eaton Vance Management sold out of Vir Biotechnology (VIR) in Q2 2022, closing a stake of 37,816 shares — an estimated $972K sold.

Eaton Vance Management first reported a position in VIR in Q1 2021 and held it in 5 quarters. The position peaked at $972K in Q1 2022. 211 funds tracked by Wall St. Rank hold VIR as of Q2 2022.

  • Eaton Vance Management reported no remaining Vir Biotechnology position as of Q2 2022 after selling out during the quarter.
  • Eaton Vance Management sold 37,816 Vir Biotechnology shares in Q2 2022, an estimated $972K.
  • Eaton Vance Management first reported a position in Vir Biotechnology in Q1 2021 and held it in 5 quarters.
  • Eaton Vance Management's Vir Biotechnology position peaked at $972K in Q1 2022.
  • 211 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2022.

Based on Eaton Vance Management's 13F filing for Q2 2022, filed 15 Aug 2022.